Royalty Pharma (RPRX) Income from Continuing Operations (2019 - 2026)
Royalty Pharma (RPRX) posted Income from Continuing Operations of 468256000.0 for Q1 2026, up 31.56% sequentially from 355913000.0 in Q4 2025, and up 7.79% YoY from 434433000.0 in Q1 2025.
Royalty Pharma (RPRX) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Income from Continuing Operations for 8 years, with the latest figure at 468256000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 7.79% year-over-year to 468256000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1359015000.0 (down 23.2% YoY) and the FY2025 annual result came in at 1324192000.0, changed 0.5% from the prior year.
- Income from Continuing Operations improved to 468256000.0 in Q1 2026 per RPRX's latest filing, from 355913000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 806358000.0 in Q3 2024 and troughed at 610030000.0 in Q4 2022.
- A 5-year average of 297318411.76 and a median of 351336000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations plunged 1236.61% in 2022, then surged 10266.93% in 2025.
- Over 5 years, Income from Continuing Operations stood at 610030000.0 in 2022, then soared by 217.63% to 717586000.0 in 2023, then sank by 53.41% to 334351000.0 in 2024, then gained by 6.45% to 355913000.0 in 2025, then surged by 31.56% to 468256000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 468256000.0, 355913000.0, and 444211000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -290.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 81.49 Mn |
| Mar 31, 2026 | 468.26 Mn |
| Dec 31, 2025 | 355.91 Mn |
| Sep 30, 2025 | 444.21 Mn |
| Jun 30, 2025 | 90.64 Mn |
| Mar 31, 2025 | 434.43 Mn |
| Dec 31, 2024 | 334.35 Mn |
| Sep 30, 2024 | 806.36 Mn |
| Jun 30, 2024 | 194.38 Mn |
| Mar 31, 2024 | -4.27 Mn |
| Dec 31, 2023 | 717.59 Mn |
| Sep 30, 2023 | 122.08 Mn |
| Jun 30, 2023 | 351.34 Mn |
| Mar 31, 2023 | 509.09 Mn |
| Dec 31, 2022 | -610.03 Mn |
| Sep 30, 2022 | 220.41 Mn |
| Jun 30, 2022 | 491.60 Mn |
| Mar 31, 2022 | 128.08 Mn |
| Dec 31, 2021 | 53.67 Mn |
| Sep 30, 2021 | 221.80 Mn |